



February 4, 2019

Company name: Mitsubishi Tanabe Pharma Corporation  
Representative: Masayuki Mitsuka,  
President and Representative Director  
Code number: 4508, First Section, Tokyo Stock Exchange  
Contact: Yoshifumi Mifune, Vice President,  
Head of Corporate Communications Department  
(TEL: +81-6-6205-5211)

## **Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka; hereinafter "MTPC") concluded a stock transfer agreement on January 31 with Nipro Pharma Corporation (Head Office: Chuo-ku, Osaka; President & Representative Director: Kenichi Nishida; hereinafter, "Nipro Pharma"). Under this agreement, MTPC's consolidated subsidiary Tanabe Seiyaku Yoshiki Factory Co., Ltd. (Head Office: Hida, Gifu Prefecture; President & Representative Director: Kenji Yogo; hereinafter, "Tanabe Seiyaku Yoshiki Factory"), will be transferred to Nipro Pharma.

### 1. Reason for transfer

In accordance with the concept of "Reforming Operational Productivity," which is one of the strategic priorities under the Medium-Term Management Plan 16-20, MTPC is advancing the reorganization and consolidation of production bases and technology functions in order to convert to a flexible, efficient production system that demonstrates strength in handling changes in the operating environment. As one part of those initiatives, MTPC decided to transfer Tanabe Seiyaku Yoshiki Factory to Nipro Pharma.

Tanabe Seiyaku Yoshiki Factory was established in 1964 as a consolidated subsidiary of MTPC. Since that time, it has developed its operations as a production base handling high-mix, low-volume pharmaceutical packaging, with strengths in low-cost, flexible operations. On the other hand, Nipro Pharma has top-class results in the domestic market for contract manufacturing of pharmaceuticals. Nipro Pharma manufactures a

diverse range of pharmaceuticals, including injections, oral preparations, and external preparations. MTPC believes that this transfer will lead to further development for Tanabe Seiyaku Yoshiki Factory, which has technologies and experience cultivated over many years of operations in pharmaceutical packaging.

## 2. Transfer method

On April 1, 2019, all of the shares of Tanabe Seiyaku Yoshiki Factory held by MTPC will be transferred to Nipro Pharma.

After the transfer, Tanabe Seiyaku Yoshiki Factory will continue to handle contract manufacturing for those MTPC products that it is currently manufacturing.

## 3. Amount of assignment

We don't disclose the transfer price due to the two companies of the arrangements.

## 4. Transfer timetable

January 31, 2019	Conclusion of stock transfer agreement
April 1, 2019 (planned)	Transfer of Tanabe Seiyaku Yoshiki Factory to Nipro Pharma

## 5. Overview of company to be transferred

Company name	Tanabe Seiyaku Yoshiki Factory Co., Ltd.
Head Office location	1-1-27, Furukawacho Koreshige, Hida, Gifu Prefecture
Representative	President & Representative Director, Kenji Yogo
Capital	¥400 million
Revenue	¥4.5 billion (fiscal 2017)
Major line of business	Pharmaceutical packaging
Number of employees	71 (as of the end of March 2018)
Shareholder	Mitsubishi Tanabe Pharma Corporation: 100%

#### 6. Overview of company to receive the transfer

Company name	Nipro Pharma Corporation
Head Office location	2-2-7, Dosho-machi, Chuo-ku, Osaka
Representative	President & Representative Director, Kenichi Nishida
Capital	¥8,669,470,000
Major lines of business	Manufacturing, sales, importing, and exporting of ethical pharmaceuticals
Number of employees	2,785 (as of the end of March 2018)

#### 7. Influence on results

There will be no effect on MTPC's results for this fiscal year.

**Mitsubishi Tanabe Pharma Corporation**  
**Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110